HHS and the White House have launched a series of National Science and Technology Challenges that use AI to tackle chronic disease, pediatric cancer research and faster therapeutic target discovery, backed by more than $5 billion in federal funding. The flagship effort aims to identify root causes of chronic disease, while additional programs are designed to accelerate drug discovery and development across large, complex datasets.

Why It Matters To Oncology

• For clinicians and oncology drug hunters, the clearest near-term relevance is AI-enabled target identification and hypothesis generation that could shorten early discovery timelines.

• HHS also explicitly tied the initiative to advancing pediatric cancer research, signaling potential support for tumor biology, biomarker discovery and prevention or treatment pathway mapping.

• The agency said researchers will use advanced AI on multi-disciplinary datasets with security and privacy protections to uncover previously unseen patterns.

The Financials

• The White House committed more than $5 billion in federal funding to support scientists using next-generation AI for health-focused discovery.

• That makes this one of the larger public-sector signals yet for AI infrastructure and challenge-based biomedical research support.

• Separate from the HHS initiative, Mentari Therapeutics said it will raise an additional $200 million, on top of a $290 million private placement announced in May, to fund migraine programs through Phase IIa readouts.

What They're Saying

• HHS said the challenges are intended to help researchers uncover hidden patterns, generate new hypotheses and identify promising pathways for prevention and treatment.

• The department emphasized use of large and complex datasets spanning multiple scientific disciplines, with appropriate security and privacy protection.

• The effort is part of President Donald Trump's Genesis Mission, which is framed around using AI for scientific discoveries.

What's Next

• Watch for details on challenge design, eligibility, timelines and how oncology-specific datasets or pediatric cancer endpoints will be incorporated.

• For drug discovery teams, the key question is whether outputs will translate into actionable targets, biomarkers or trial-enrichment strategies.

• Also on the horizon: AstraZeneca's Phase III DepleTTR-CM readout for cliramitug is expected in 2028, following Royalty Pharma's deal worth up to $425 million for part of Neurimmune's royalty interest.